Last update 04 Nov 2024

Olanzapine

Overview

Basic Info

SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder.
Drug Type
Small molecule drug
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, mdc-TJK, Olanzapin
+ [35]
Mechanism
5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC17H20N4S
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Registry132539-06-1

External Link

KEGGWikiATCDrug Bank
D00454Olanzapine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chemotherapy-induced nausea and vomiting
JP
25 Dec 2017
Chemotherapy-induced nausea and vomiting
JP
25 Dec 2017
Agitation
US
19 Mar 2009
Depressive Disorder
US
19 Mar 2009
Depressive Disorder, Treatment-Resistant
US
19 Mar 2009
Bipolar and Related Disorders
CN
01 Jan 2006
Bipolar I disorder
US
30 Sep 1996
Bipolar Disorder
EU
27 Sep 1996
Bipolar Disorder
IS
27 Sep 1996
Bipolar Disorder
LI
27 Sep 1996
Bipolar Disorder
NO
27 Sep 1996
Mania
EU
27 Sep 1996
Mania
IS
27 Sep 1996
Mania
LI
27 Sep 1996
Mania
NO
27 Sep 1996
Schizophrenia
EU
27 Sep 1996
Schizophrenia
IS
27 Sep 1996
Schizophrenia
LI
27 Sep 1996
Schizophrenia
NO
27 Sep 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
CN
01 Oct 2020
VomitingPhase 3
CN
01 Oct 2020
GamblingPhase 3
US
01 Feb 2007
Weight GainPhase 3
US
01 Nov 2006
Weight GainPhase 3
BR
01 Nov 2006
Weight GainPhase 3
IL
01 Nov 2006
Weight GainPhase 3
MX
01 Nov 2006
Weight GainPhase 3
PR
01 Nov 2006
Weight GainPhase 3
RU
01 Nov 2006
Weight GainPhase 3
KR
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
675
TEV-‘749 531 mg
bddhzbglxd(bifjesxrxe) = wxbihuhqgg gpgpnceeie (kszefqecsa )
Positive
26 Sep 2024
TEV-‘749 425 mg
bddhzbglxd(bifjesxrxe) = xmdnlobmfr gpgpnceeie (kszefqecsa )
Phase 2
168
(the delayed phase)
bvsemlkgmt(qkvaisuedl) = mthtmoscwf lyesfionvd (hbpzkwxfht )
Met
Positive
14 Sep 2024
Placebo
(the delayed phase)
bvsemlkgmt(qkvaisuedl) = lhpjzijodt lyesfionvd (hbpzkwxfht )
Met
Not Applicable
-
1,933
dbfruoizss(pbyisqamkn) = wfzqzljuuk iglzjigmls (egjfnhccaw )
Positive
14 Sep 2024
No Olanzapine
dbfruoizss(pbyisqamkn) = ovsdtblkki iglzjigmls (egjfnhccaw )
Phase 3
675
TEV-'749 high dose
jkdvufwsdm(cotksypaxw) = mrxsvigirm rasexsaelh (wyohgyycwx )
Met
Positive
08 May 2024
TEV-'749 medium dose
jkdvufwsdm(cotksypaxw) = uqnmctjfmv rasexsaelh (wyohgyycwx )
Met
Phase 3
52
80 mg orally on Days 0
(Aprepitant)
iauxdeqcid(slabcljpme) = cvezsgjjac vwnvuoeext (mlxowffghs, hxwkughtzo - zilpdxvdqb)
-
22 Jan 2024
+2
(Olanzapine)
iauxdeqcid(slabcljpme) = pjfaaicuof vwnvuoeext (mlxowffghs, fruizeaixj - jpufvmnoli)
Not Applicable
30
wxlflxsihg(dhhzyqmdmz) = ducfhqdldu voilmsijic (agdizvxmka )
-
02 Dec 2023
Not Applicable
Add-on
84
svftpcphpt(smoasnmabb) = kjjvaxcedf sdgpdrezts (xglyhsanml )
-
02 Dec 2023
Placebo
svftpcphpt(smoasnmabb) = ccndetnmgi sdgpdrezts (xglyhsanml )
ESMO2023
ManualManual
Phase 2
76
zophybgbba(tsvfqmgefu) = kbeoxerllm xzdmlxiepb (yidndidhil, 9.4 - 27.5)
Negative
21 Oct 2023
Phase 3
544
(Standard antiemetic prophylaxis)
prhjsjbcgy(epsgkeyvgo) = ozojwgwqzw xtkdgarhpu (ciqruqtijn )
Positive
21 Oct 2023
Standard antiemetic prophylaxis + Olanzapine
prhjsjbcgy(epsgkeyvgo) = evmewuvqrd xtkdgarhpu (ciqruqtijn )
Phase 3
91
(Usual Care)
reazekqywx(twgmgnojyp) = uepsytaahc nqwafvimwt (oaclxxyvmh, ixqisovwtx - peaieihyiv)
-
09 May 2023
(Olanzapine)
lrqidiwuio(phfexefsls) = gzgcyopntr jogaxzsrno (uwvkcppzyb, rimdslpqpv - gscrevoljt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free